Loading...
Loading...
Alnylam Pharmaceuticals, Inc.
ALNY, a leading RNAi therapeutics
company, today announced that the underwriters of its previously announced
public offering of common stock have exercised their option to purchase an
additional 1,200,000 shares at the public offering price of $20.13 per share.
As a result, the company will issue a total of 9,200,000 shares in the
offering and will receive aggregate net proceeds, after underwriting discounts
and commissions and other estimated offering expenses, of approximately $173.8
million. The offering is expected to close on or about January 22, 2013,
subject to the satisfaction of customary closing conditions.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in